Loading market observation…
Loading research…
Model estimates are informational, not investment advice. They are uncertain, may be wrong, and do not guarantee future prices.
Latest observed price
$72.47
Session change unavailableStatus checked Oct 25, 2026, 2:37 PM · America/New_York
Observed Sep 21, 2026, 8:00 PM UTC · Last available price
The latest observed price above is market data. Forecast starting prices are issuance-frozen values and are labelled separately in Model Forecast below.
Review the dated model forecast and five-factor Scorecard for TECH. Each has its own availability and reference date; a score is a relative comparison, not a price prediction.
Lower Estimate (P10)
$44.63
-38.4%
Median Estimate (P50)
$79.22
+9.3% from starting price
Upper Estimate (P90)
$119.82
+65.3%
The estimate uses its dated starting price. It does not predict returns from today’s quote.
View forecast details, dates and available rangesLoading research…
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Loading research…
Risk / safety methodology: Safety describes recent price swings and distance from a recent high alongside cash flow and profitability. It is not a credit rating or a promise of protection from loss.
Multi-factor scoring at a glance
Individual factor readings · Shading shows available dimensions only. Overall requires all five scores and a comparable peer group.
A combined view of Value, Quality, Growth, Safety and Momentum. Review the factor breakdown alongside the total.
Scores and key insights for each dimension
How its fundamental growth measures compare.
How its valuation measures compare with the group.
How its profitability and operating quality compare.
How its price swings, distance from a recent high, cash flow and profitability compare.
How its recent price-trend measures compare.
All scores in this Scorecard describe relative characteristics as of the shown date, using historical market data and reported company information; higher scores on the 0–100 scale indicate more favorable characteristics in the relevant comparison group, and none forecasts future performance.
Higher scores indicate higher relative readings.
Upgrade to Pro to explore this analysis.
Scores are relative comparisons, not absolute grades: companies with different coverage may be scored on different inputs. Peer positions and input coverage can differ by factor; use the displayed comparison group and date when comparing readings. An 80 is not an 80% chance of a price rise. These scores are not price forecasts or recommendations.
The rank with complete inputs compares only companies with every input for that factor, using the issued scores. Equal partial coverage percentages do not establish matching inputs. Current stockwide snapshots use matching input groups; older snapshots may use a smaller fixed group. Scores do not separately adjust for industry or company size. Growth readings do not establish multi-year persistence or separate share-count effects from EPS growth. Scores are independent of the selected forecast horizon.
Latest update · 2026-09-21
View Plans to read the previous successful update.
Previous update means the last successfully published update, including across weekends and market holidays. The Analysis tab keeps the information used in its latest report.
Open a ready-made screen, review its filters and adapt it to your questions.
Upgrade to Plus or Pro to explore this analysis.
Upgrade to Plus or Pro to explore this analysis.
Upgrade to Plus or Pro to explore this analysis.
A comparison appears after a previous update is available.
Upgrade to Plus or Pro to explore this analysis.
Start with profit, cash generation and financial flexibility. Scores describe relative characteristics and do not predict returns.
Market observations, financial reporting periods and report dates can differ. Each measure shows its own period.
Compare company metrics only when their currency, observation date and reporting periods agree. Similar companies are starting points for research, not substitutes for each other.
Upgrade to Plus or Pro to explore this analysis.
Economic observations provide background. Observation periods and release dates can differ; these readings do not establish a company-specific effect.
Unavailable
Reported ownership and transaction amounts are disclosure observations, not investment instructions. Filing dates can lag the transaction date.
Unavailable
New filing entries since the previous update. An entry does not establish a change in the document's contents.
Keep your own questions and observations with this company.
Sign in to save a noteExplore related companies in our coverage. Open a stock for its full forecast and Scorecard.
BMRN
Latest observed price
$64.06
Observed
Sep 21, 2026
12-month forecast
Median (P50)
$68.31
+6.6%
From $64.06 starting price
Target Sep 21, 2027
Overall Score
ModerateForecast basis Sep 21, 2026
Score date Sep 22, 2026
EXEL
Latest observed price
$57.22
Observed
Sep 21, 2026
12-month forecast
Median (P50)
—
Overall Score
StrongForecast basis —
Score date Sep 22, 2026
MDGL
Latest observed price
$521.96
Observed
Sep 21, 2026
12-month forecast
Median (P50)
$597.42
+14.5%
From $521.96 starting price
Target Sep 21, 2027
Overall Score
UnavailableForecast basis Sep 21, 2026
Score date —
MRNA
Latest observed price
$172.94
Observed
Sep 21, 2026
12-month forecast
Median (P50)
$204.51
+18.3%
From $172.94 starting price
Target Sep 21, 2027
Overall Score
UnavailableForecast basis Sep 21, 2026
Score date —
12-month forecasts show model median estimates (P50), with changes from each forecast’s starting price. Headline scores describe dated company characteristics; they do not predict future performance.
